GSK revamps selling model

December 2007
Pharmaceutical Representative;Dec2007, Vol. 37 Issue 12, p10
The article reports on the move of GlaxoSmithKline in London to adapt its worldwide selling model. The firm, with headquarters in Philadelphia, is making the move to respond to the present market conditions in relation to its changing product portfolio and recent sales force pilot initiatives. The firm's plans include a shift in resources toward growing therapeutic areas like oncology and vaccines.


Related Articles

  • Listen to the pharma giant. Spadaccino, Jo // PRWeek (London);Feb2011 Advertising Supplement, p19 

    The article talks about GlaxoSmith Kline's (GSK) business strategy and the British pharmaceutical industry. The author believes that GSK's business strategies of honesty, transparency, and focus on improving health outcomes rather than changing products can be emulated by the rest of the pharma...

  • GSK looks to gain from pain relief sector shake-up. Jack, Louise // Marketing Week;11/20/2008, Vol. 31 Issue 47, p11 

    The article reports that the pharmaceutical company GlaxoSmithKline (GSK) has launched a new variant of the analgesic brand Panadol for pain relief in Great Britain. The company is planning the renovation of its operational structure and modernization due to decreasing profits. Panadol is...

  • Mind the Gap. Morais, Richard C. // Forbes Global;7/21/2003, Vol. 6 Issue 15, p44 

    Features GlaxoSmithKline and the restructuring of the way it discovers drugs. Limitation in the merger between British pharmaceuticals Glaxo Wellcome and SmithKline Beecham; Reason behind the decision to terminate the merger's hierarchical research pyramid; Use of a miniaturization process at...

  • Forecast--and Fast. Clinton, Patrick // Pharmaceutical Executive;Jun2006, Vol. 26 Issue 6, p18 

    The article discusses the challenges faced by pharmaceutical companies in developing medicines in the pharmaceutical industry in the U.S. Companies need a business model to develop medicines that could cure disease which have never been successfully treated before. Life-threatening diseases such...

  • SYSTEMS BIOLOGY'S Awkward Adolescence. Russell, John // Bio-IT World;Sep2007, Vol. 6 Issue 7, p20 

    The article ponders on the role of systems biology (SB) in the pharmaceutical industry and biotechnology. Novartis and GlaxoSmithKline, which are considered the early advocates of SB, have disbanded or deemphasized internal SB departments. Observers think that their action is simply...

  • Drug Discovery Technology World Congress Program Is Like Five-in-One.  // Drug Discovery & Development;Jul2004, Vol. 7 Issue 7, p72 

    Provides information on the Drug Discovery Technology World Congress meeting by IBC USA Inc. Date and venue; Focus on drug discovery, biotherapeutics, business strategy and informatics; Awards to be given.

  • Fate Tempts VCs With Stem Cell Business Model.  // Bioworld Week;12/10/2007, Vol. 15 Issue 50, p2 

    The article reports that Fate Therapeutics of Seattle, Washington, has raised $12 million in a Series A financing to pursue in vivo and ex vivo modulation of adult stem cells. ARCH Venture Partners, Polaris Venture Partners and Venrock Associates were among the investors included in the round....

  • GSK's Academic Competition Aims to Accelerate Innovation. Moran, Nuala // BioWorld International;5/22/2013, Vol. 18 Issue 21, p1 

    The article reports that British pharmaceutical company GlaxoSmithKline (GSK) has launched Discovery Fast Track, a competition aiming to accelerate innovation in drug development. Academics participating in the competition will outline their novel drug development concept. Winners in the...

  • GSK's Academic Competition Aims to Accelerate Innovation. Moran, Nuala // BioWorld Today;5/22/2013, Vol. 24 Issue 98, p1 

    The article features the Discovery Fast Track, a competition on drug development concept sponsored by GlaxoSmithKline (GSK) plc for academics in North America. The entry should be a one-page proposal on any therapeutic field to be submitted before July 19, 2013, wherein the 10 winner will be...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics